Rchr
J-GLOBAL ID:201901011715996968
Update date: Sep. 15, 2024 Masuda Muneyuki
Masuda Muneyuki
Affiliation and department: Job title:
Deputy Director of the Center
Research field (1):
Otorhinolaryngology
Research keywords (4):
epigenetics
, molecular biology
, head and neck surgery
, head and neck cancer
Research theme for competitive and other funds (13): - 2022 - 2027 側頭骨扁平上皮癌の悪性度を決定するエピジェネティックな腫瘍制御機構の解明
- 2021 - 2024 Roles of tissue degenerative tansscriptional reprogramming in the evolution of head and neck cancer
- 2021 - 2024 頭頸部・食道の損傷・修復異常に着目した発癌・進展の機序解明と個別化治療戦略の確立
- 2018 - 2021 Molecular mechanism of carcinogenesis of head and neck and esophagus induced by cigarette smoking and alcohol drinking: Aiming to establishment of personalized treatment strategy
- 2016 - 2019 Epigenetic reprogramming in head and neck cancer
- 2016 - 2019 The role of epigenetic reprogramming for the acquisition of pluripotency in head and neck cancer stem cells
- 2015 - 2018 Molecular mechanism of development and progression of upper aerodigestive tract cancer induced by cigarette smoking and alcohol drinking
- 2015 - 2017 Research for relationship between oral microboiome and head and neck and digestive organ cancers
- 2012 - 2015 Latent vulnerability of head and neck cancer-exploration and exploitation as a molecular target
- 2009 - 2011 Stat3 targeted therapy in head and neck cancer
- 2004 - 2004 増殖シグナルを標的とした頭頚部癌治療の研究
- 2001 - 2003 Significance of extra-cellular matrices and adhesion molecules in the pen-neural invasion of head and neck carcinomas
- 1999 - 2000 頭頚部癌培養細胞に対するアンチセンスcyclinD1の導入実験
Show all
Papers (144): -
Mioko Matsuo, Muneyuki Masuda, Moriyasu Yamauchi, Kazuki Hashimoto, Ryunosuke Kogo, Masanobu Sato, Shogo Masuda, Takashi Nakagawa. Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation. Cancers. 2024. 16. 14
-
Hirofumi Omori, Takahiro Wakasaki, Takahiro Hongo, Fumihide Rikimaru, Satoshi Toh, Yuichiro Higaki, Muneyuki Masuda. Acquired tracheobronchomalacia developed following voice prosthesis implantation. Auris, nasus, larynx. 2024. 51. 3. 433-436
-
Takahiro WakasakiI, Tomomi Manako, Ryuji YasumatsuI, Hirotaka Hara, Satoshi Toh, Muneyuki Masuda, Moriyasu YamauchiID, Yuichiro Kuratomi, Emi Nishimura, Toranoshin Takeuchi, et al. Erratum: Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study (PloS one (2022) 17 7 (e0271907)). PloS one. 2024. 19. 5. e0303720
-
益田 宗幸, 藤 賢史, 佐藤 晋彰, 松尾 未央子, 菅澤 正, 山崎 惠介, 植木 雄志, 中島 寅彦, 瓜生 英興, 小野 剛治, et al. 頭頸部癌患者血漿exosome mRNA網羅的解析によるニボルマブ治療効果予測因子の同定. 日本癌治療学会学術集会抄録集. 2023. 61回. SP-4
-
Kuniaki Sato, Satoshi Toh, Taku Murakami, Takafumi Nakano, Takahiro Hongo, Mioko Matsuo, Kazuki Hashimoto, Masashi Sugasawa, Keisuke Yamasaki, Yushi Ueki, et al. Prospective exploration of a prognostic biomarker of nivolumab for head and neck cancer patients (BIONEXT). 2023
more... MISC (221): -
大森裕文, 大森裕文, 益田宗幸, 佐藤晋彰, 中野貴史, PENNINGER Josef. YAP1による転写リプログラミングは頭頸部癌共生的進化の推進力である. 日本頭頸部外科学会総会ならびに学術講演会プログラム・予稿集. 2023. 32nd (CD-ROM)
-
橋本和樹, 安松隆治, 松尾美央子, 若崎高裕, 次郎丸梨那, 真子知美, 山元英崇, 久我亮介, 益田宗幸, 倉富勇一郎, et al. 唾液腺癌に対する免疫チェックポイント阻害薬の臨床効果に関する検討. 頭頸部癌. 2021. 47. 2
-
影山 伸哉, 竹下 徹, 竹内 研時, 朝川 美加李, 古田 美智子, 柴田 幸江, 山下 喜久, 永井 清志, 池部 正彦, 森田 勝, et al. 消化管がん患者の唾液マイクロバイオームに特徴的な細菌種の同定. 口腔衛生学会雑誌. 2020. 70. 増刊. 149-149
- 益田 宗幸. どこまで進んでいるの?NGS(次世代シーケンサー)テクノロジーの頭頸部癌への応用. 頭頸部癌. 2019. 45. 2. 84-84
- 次郎丸 梨那, 山元 英崇, 安松 隆治, 本郷 貴大, 野崎 優衣, 橋本 和樹, 田口 健一, 益田 宗幸, 中川 尚志, 小田 義直. 鼻副鼻腔癌におけるHPV感染とEGFR遺伝子コピー数増加の予後に及ぼす影響. 頭頸部癌. 2019. 45. 2. 145-145
more... Return to Previous Page